Orphan Diseases Therapeutics in CNS to 2017 - Novel Agents such as AMR101 and ACR16 to Provide Treatment Options and Boost the Huntington's Disease Segment
NEW YORK, June 28, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Orphan Diseases Therapeutics in CNS to 2017 - Novel Agents such as AMR101 and ACR16 to Provide Treatment Options and Boost the Huntington's Disease Segmenthttp://www.reportlinker.com/p0832794/Orphan-Diseases-Therapeutics-in-CNS-to-2017---Novel-Agents-such-as-AMR101-and-ACR16-to-Provide-Treatment-Options-and-Boost-the-Huntington's-Disease-Segment.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy
Orphan Diseases Therapeutics in CNS to 2017 - Novel Agents such as AMR101 and ACR16 to Provide Treatment Options and Boost the Huntington's Disease Segment
Summary Huntington Europe JapanGBI Research's analysis shows that the overall global CNS orphan disease market is set to increase over the forecast period. It grew from $359.6m in 2002 to $665.5m in 2010 at a Compound Annual Growth Rate (CAGR) of 8%. This is projected to increase to a CAGR of 17.6% over the forecast period to $2.1 billion in 2017. The global ALS therapeutics market generated approximately $163.2m in 2010, growing from $109.7m in 2002 at a CAGR of 5.1%. By 2017, this is expected to have increased to $210.5m at a CAGR of 3.7%. ALS was one of the biggest orphan CNS disease markets globally in 2010. The global HD therapeutics market generated approximately $126.7m in 2010, growing from $34.3m in 2002 at a CAGR of 17.8%. By 2017, this is expected to have increased to $786.5m at a CAGR of 29.8%. Globally, the MG therapeutics market increased from $42.5m in 2002 to $57.7m in 2010 at a CAGR of 3.9%. Over the forecast period it is expected to grow to $88.6m in 2017 with a higher CAGR of 6.3%.
Scope
- The report analyzes treatment usage patterns, market characterization, pipeline analysis, competitive landscape and key M&A trends in the global orphan diseases therapeutics in CNS market for three indications, amyotrophic lateral sclerosis, huntington's disease and myasthenia gravis.- Data and analysis on the orphan diseases therapeutics in CNS market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain and Japan.- Annualized market data for the orphan diseases therapeutics in CNS market from 2004 to 2010, with forecasts to 2017.- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.- Share of the generics in global orphan diseases therapeutics in CNS market and for the market of each indication that is covered in the report.- Key drivers and restraints that have had a significant impact on the market.- The competitive landscape of the global market including top companies benchmarking. The key companies studied in this report are Biogen Idec, Avanir Pharmaceuticals, Neuraltus Pharmaceuticals, Cytokinetics, The Avicena Group, NeuroSearch, Trophos, Amarin Corporation, Siena Biotech, Sanofi.- Key M&A activities and licensing agreements that took place between 2004 and 2011 in the orphan diseases therapeutics in CNS market.
Reasons to buy
The report will assist business development and marketing executives to strategize their product launches, by allowing them to - - Align your product portfolio to the markets with high growth potential.- Build effective strategies to launch their pipeline products by identifying potential geographies.- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.- Develop key strategic initiatives by studying the key strategies of top competitors.- Create a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication.- Develop market entry and market expansion strategies by identifying the geographic markets poised for strong growth.- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.1 Table of Contents1 Table of Contents 31.1 List of Tables 51.2 List of Figures 72 Orphan Diseases Therapeutics in CNS - Introduction 92.1 GBI Research Report Guidance 103 Orphan Diseases Therapeutics in CNS - Market Overview 113.1 Introduction 113.2 Orphan Disease Regulation and Incentives 113.3 Global Revenue Forecasts for Orphan Diseases Therapeutics in CNS 133.3.1 Global Revenue and Forecast 133.3.2 Geographical Segmentation 153.3.3 Branded and Generic Market Share 173.3.4 Revenue Share by Indication 183.3.5 Market Drivers 203.3.6 Market Restraints 213.3.7 Unmet Needs 213.3.8 Opportunities 224 Orphan Diseases Therapeutics in CNS - Geographical Landscape 234.1 The US 234.1.1 Revenue 234.2 Top Five Countries of Europe 254.2.1 Revenue 254.3 Japan 264.3.1 Revenue 265 Orphan Diseases in CNS Disorders - Therapeutic Landscape 275.1 Amyotrophic Lateral Sclerosis 275.1.1 Disease Overview 275.1.2 Revenue 275.1.3 Average Annual Cost of Treatment 315.1.4 Branded and Generic Market Share 335.1.5 Treatment Algorithm 345.1.6 Treatment Usage Patterns 345.1.7 Approved Molecules 415.1.8 Rilutek 415.1.9 Nuedexta (Dextromethorphan Hydrobromide and Quinidine Sulfate) 425.2 Huntington's Disease 435.2.1 Disease Overview 435.2.2 Total Revenue 445.2.3 Average Annual Cost of Treatment (ACT) 475.2.4 Branded and Generic Market Share 485.2.5 Treatment Algorithm 495.2.6 Treatment Usage Patterns 505.3 Approved Molecules 545.3.1 Xenazine (tetrabenazine) 545.4 Myasthenia Gravis 555.4.1 Disease Overview 555.4.2 Total Revenue 565.4.3 Branded and Generic Market Share 595.4.4 Average Annual Cost of Treatment 605.4.5 Treatment Algorithm 615.4.6 Treatment Usage Patterns 625.4.7 Approved Molecules 665.5 Other Indications 675.5.1 Total Revenue 675.5.2 Product Profiles 686 Global Orphan Diseases in CNS Disorders - Pipeline Analysis 716.1 Introduction 716.2 Research and Development Pipeline 726.2.1 Overview 726.2.2 Pipeline by Clinical Phases of Development 756.2.3 Profiles of Promising Drugs in Orphan Diseases in CNS Disorders 827 Global Orphan Diseases in CNS Disorders - Competitive Landscape 857.1 Major Players 857.2 Major Company Profiles 857.2.1 Biogen Idec 857.2.2 Avanir 867.2.3 Neuraltus 877.2.4 Cytokinetics 887.2.5 Avicena 897.2.6 NeuroSearch 907.2.7 Trophos 917.2.8 Amarin 927.2.9 Siena Biotech 937.2.10 Sanofi 948 Global Orphan Diseases in CNS Disorders - Strategic Consolidations 958.1 Mergers and Acquisitions 958.1.1 Overview 958.1.2 Major Mergers and Acquisitions Deals 978.1.3 Segmentation by Indication 988.1.4 Segmentation by Geography 998.1.5 Segmentation by Deal Value 1008.1.6 Segmentation by Year 1018.2 Licensing Agreements 1028.2.1 Overview 1028.2.2 Major Licensing Deals 1058.2.3 Segmentation by Indication 1078.2.4 Segmentation by Geography 1088.2.5 Segmentation by Deal Value 1098.2.6 Segmentation by Year 1108.3 Co Development Deals 1118.3.1 Segmentation by Geography 1138.3.2 Segmentation by Value 1148.3.3 Segmentation by Year 1159 CNS Orphan Diseases - Appendix 1169.1 Market Definition 1169.2 Abbreviations 1169.3 Research Methodology 1179.3.1 Coverage 1189.3.2 Secondary Research 1189.3.3 Primary Research 1189.4 Forecasting 1199.4.1 Epidemiology-based Forecasting 1199.4.2 Expert Panels Validation 1209.5 Contact Us 1209.6 Disclaimer 1209.7 Sources 120
1.1 List of Tables
Table 1: Orphan Diseases Therapeutics in CNS, Global, Revenue ($m), 2002–2010 13Table 2: Orphan Diseases Therapeutics in CNS, Global, Revenue Forecasts ($m), 2010–2017 13Table 3: Orphan Diseases Therapeutics in CNS, Global, Revenue Segmentation by Geography, ($m), 2002–2010 15Table 4: Orphan Diseases Therapeutics in CNS, Global, Revenue Segmentation by Geography, ($m), 2010–2017 16Table 5: Orphan Diseases Therapeutics in CNS, Global, Revenues by Indication ($m), 2002-2010 18Table 6: Orphan Diseases Therapeutics in CNS, Global, Revenues by Indication ($m), 2010-2017 18Table 7: Orphan Diseases Therapeutics in CNS, The US, Revenues, ($m), 2002–2010 23Table 8: Orphan Diseases Therapeutics in CNS, The US, Revenue Forecasts, ($m), 2010–2017 23Table 9: Orphan Diseases Therapeutics in CNS, Top Five Countries of Europe, Revenues ($m), 2010–2017 25Table 10: Orphan Diseases Therapeutics in CNS, Top Five Countries of Europe, Revenue Forecasts ($m), 2010–2017 25Table 11: Orphan Diseases Therapeutics in CNS, Japan, Revenues ($m), 2002–2010 26Table 12: Orphan Diseases Therapeutics in CNS, Japan, Revenue Forecasts ($m), 2010–2017 26Table 13: ALS Therapeutics, Global, Revenues ($m), 2002–2010 28Table 14: ALS Therapeutics, Global, Revenue Forecasts ($m), 2010–2017 28Table 15: ALS Therapeutics, Global, Revenue by Geographical Segmentation ($m), 2002–2010 29Table 16: ALS Therapeutics, Global, Revenue by Geographical Segmentation ($m), 2010–2017 30Table 17: ALS Therapeutics, Global, Annual Cost of Therapy ($), 2002–2010 31Table 18: ALS Therapeutics, Global, Annual Cost of Therapy ($m), 2010–2017 31Table 19: ALS Therapeutics Market, Global, Generic and Branded Revenues ($m), 2010 and 2017 33Table 20: ALS Therapeutics Market, Global, Diseased Population ('000), 2002–2010 34Table 21: ALS Therapeutics Market, Global, Diseased Population ('000), 2010–2017 35Table 22: ALS Therapeutics Market, Global, Treatment Seeking Population ('000), 2002–2010 36Table 23: ALS Therapeutics Market, Global, Treatment Seeking Population ('000), 2010–2017 36Table 24: ALS Therapeutics, Global, Diagnosed Population ('000), 2002–2010 38Table 25: ALS Therapeutics, Global, Diagnosed Population ('000), 2010-2017 38Table 26: ALS Therapeutics, Global, Prescription Population ('000), 2002–2010 40Table 27: ALS Therapeutics, Global, Prescription Population ('000), 2010–2017 40Table 28: HD Therapeutics Market, Global, Revenues ($m), 2002–2010 44Table 29: HD Therapeutics Market, Global, Revenue Forecasts ($m), 2010–2017 44Table 30: HD Therapeutics, Global, Revenue Segmentation by Country ($m), 2002–2010 46Table 31: HD Therapeutics, Global, Revenue Forecasts Segmentation by Country ,($m), 2010–2017 46Table 32: HD Therapeutics, Global, Annual Cost of Therapy ($), 2002-2010 47Table 33: HD Therapeutics, Global, Annual Cost of Therapy ($), 2010–2017 47Table 34: HD Therapeutics Market, Global, Generic and Branded Revenues ($m), 2010 and 2017 48Table 35: HD Therapeutics, Global, Diseased Population ('000), 2002–2010 50Table 36: HD Therapeutics, Global, Diseased Population ('000), 2010–2017 50Table 37: HD Therapeutics, Global, Treatment Seeking Population ('000), 2002–2010 51Table 38: HD Therapeutics, Global, Treatment Seeking Population ('000), 2010–2017 51Table 39: HD Therapeutics, Global, Diagnosed Population ('000), 2002–2010 52Table 40: HD Therapeutics, Global, Diagnosed Population ('000), 2010–2017 52Table 41: HD Therapeutics, Global, Prescription Population ('000), 2002–2010 53Table 42: HD Therapeutics, Global, Prescription Population ('000), 2010–2017 53Table 43: MG Therapeutics, Global, Revenues ($m), 2002–2010 56Table 44: MG Therapeutics, Global, Revenue Forecasts ($m), 2010–2017 56Table 45: MG Therapeutics, Global, Revenue Segmentation by Geography, ($m), 2002–2010 57Table 46: MG Therapeutics, Global, Revenue Forecasts Segmentation by Geography, ($m), 2010-2017 58Table 47: MG Therapeutics Market, Global, Branded and Generic Revenues ($m), 2010 and 2017 59Table 48: MG Therapeutics, Global, Annual Cost of Therapy ($m), 2002–2010 60Table 49: MG Therapeutics, Global, Annual Cost of Therapy ($m), 2010–2017 60Table 50: MG Therapeutics, Global, Diseased Population ('000), 2002–2010 62Table 51: MG Therapeutics, Global, Diseased Population ('000), 2010–2017 62Table 52: MG Therapeutics, Global, Treatment Seeking Population ('000), 2002–2010 63Table 53: MG Therapeutics, Global, Treatment Seeking Population ('000), 2010–2017 63Table 54: MG Therapeutics, Global, Diagnosed Population ('000), 2002–2010 64Table 55: MG Therapeutics, Global, Diagnosed Population ('000), 2010–2017 65Table 56: MG Therapeutics, Global, Prescription Population ('000), 2002–2010 65Table 57: MG Therapeutics, Global, Prescription Population ('000), ($m), 2010–2017 66Table 58: Other CNS Orphan Disease Therapeutics, Global, Revenues ($m), 2002–2010 67Table 59: Other CNS Orphan Disease Therapeutics, Global, Revenue Forecasts ($m), 2010–2017 67Table 60: Orphan Diseases Therapeutics in CNS, Global, Discovery Pipeline Molecules, 2011 75Table 61: Orphan Diseases Therapeutics in CNS, Global, Pre-clinical Pipeline Molecules, 2011 76Table 62: Orphan Diseases Therapeutics in CNS, Global, IND Filed Molecules, 2011 78Table 63: Orphan Diseases Therapeutics in CNS, Global, Phase I Pipeline Molecules, 2011 79Table 64: Orphan Diseases Therapeutics in CNS, Global, Phase II Pipeline Molecules, 2011 80Table 65: Orphan Diseases Therapeutics in CNS, Global, Phase III Pipeline Molecules, 2011 81Table 66: Orphan Diseases Therapeutics in CNS, Global, M&A Deal, 2004–2011 96Table 67: Orphan Diseases Therapeutics in CNS, Global, Licensing Agreements, by Year, 2004–2012 102Table 68: Orphan Diseases Therapeutics in CNS, Global, Co-development Deals by Year, 2009–2011 111Table 69: Orphan Diseases Therapeutics in CNS, Global, Co-development Deals by Year, 2009–2011 112
1.2 List of Figures
Figure 1: Orphan Diseases Therapeutics in CNS, Global, Revenue , ($m), 2002–2017 13Figure 2: Orphan Diseases Therapeutics in CNS, Global, Revenue Segmentation by Geography, ($m), 2002–2017 15Figure 3: Orphan Diseases Therapeutics in CNS, Global, Branded and Generic Market Share (%), 2010 17Figure 4: Orphan Diseases Therapeutics in CNS, Global, Revenue by Indication, ($m) 2002–2017 18Figure 5: Orphan Diseases Therapeutics in CNS Market, Drivers and Restraints 20Figure 6: Orphan Diseases Therapeutics in CNS, The US, Revenue, ($m), 2002–2017 23Figure 7: Orphan Diseases Therapeutics in CNS, Top Five Countries of Europe, Revenues ($m), 2002–2017 25Figure 8: Orphan Diseases Therapeutics in CNS, Japan, Revenue ($m), 2002–2017 26Figure 9: ALS Therapeutics Market, Global, Revenue ($m), 2002–2017 27Figure 10: ALS Therapeutics, Global, Revenue by Geography ($m), 2002–2017 29Figure 11: ALS Therapeutics, Global, Annual Cost of Treatment ($m), 2002–2017 31Figure 12: ALS Therapeutics Market, Global, Branded and Generic Market Share (%), 2010 and 2017 33Figure 13: ALS Therapeutics Market, Global, Diseased Population (Hundreds), 2002–2017 34Figure 14: ALS Therapeutics, Global, Treatment Seeking Population (Hundreds), 2002–2017 36Figure 15: ALS Therapeutics, Global, Diagnosed Population (Hundreds), 2002–2017 38Figure 16: ALS Therapeutics, Global, Prescription Population (Hundreds), 2002–2017 40Figure 17: HD Therapeutics Market, Global, Revenues ($m), 2002–2017 44Figure 18: HD Therapeutics Market, Global, Revenues by Country ($m), 2002–2017 45Figure 19: HD Therapeutics Market, Global, Annual Cost of Therapy ($), 2002–2017 47Figure 20: HD Therapeutics Market, Global, Branded and Generic Market Share (%), 2010 and 2017 48Figure 21: HD Therapeutics, Treatment Algorithm, 2010 49Figure 22: HD Therapeutics, Global, Diseased Population ('000), 2002–2017 50Figure 23: HD Therapeutics, Global, Treatment Seeking Population ('000), 2002–2017 51Figure 24: HD Therapeutics, Global, Diagnosed Population ('000), 2002–2017 52Figure 25: HD Therapeutics, Global, Prescription Population ('000), 2002–2017 53Figure 26: MG Therapeutics, Global, Revenues ($m), 2002–2017 56Figure 27: MG Therapeutics, Global, Revenues by Country ($m), 2002–2017 57Figure 28: MG Therapeutics Market, Global, Branded and Generic Market Share (%), 2010 and 2017 59Figure 29: MG Therapeutics, Global, Annual Cost of Therapy ($m), 2002–2017 60Figure 30: MG Therapeutics, Treatment Algorithm, 2010 61Figure 31: MG Therapeutics, Global, Diseased Population ('000), 2002–2017 62Figure 32: MG Therapeutics, Global, Treatment Seeking Population ('000), 2002–2017 63Figure 33: MG Therapeutics, Global, Diagnosed Population ('000), 2002–2017 64Figure 34: MG Therapeutics, Global, Prescription Population ('000), 2002–2017 65Figure 35: Other Orphan CNS Therapeutics, Global, Revenues ($m), 2002-2017 67Figure 36: Orphan Diseases Therapeutics in CNS, Global, R&D Pipeline by Stage of Development (%), 2011 72Figure 37: ALS Therapeutics Market, Global, R&D Pipeline by Stage of Development (%), 2011 72Figure 38: HD Therapeutics Market, Global, R&D Pipeline by Stage of Development (%), 2011 73Figure 39: MG Therapeutics Market, Global, R&D Pipeline by Clinical Stage of Development (%), 2011 73Figure 40: Orphan Diseases Therapeutics in CNS, Global, SWOT –Biogen, 2011 85Figure 41: Orphan Diseases Therapeutics in CNS, Global, SWOT –Avinar, 2011 86Figure 42: Orphan Diseases Therapeutics in CNS, Global, SWOT –Neuraltus, 2011 87Figure 43: Orphan Diseases Therapeutics in CNS, Global, SWOT –Cytokinetics, 2011 88Figure 44: Orphan Diseases Therapeutics in CNS, Global, SWOT –Avicena, 2011 89Figure 45: Orphan Diseases Therapeutics in CNS, Global, SWOT –NeuroSearch, 2011 90Figure 46: Orphan Diseases Therapeutics in CNS, Global, SWOT –Trophos, 2011 91Figure 47: Orphan Diseases Therapeutics in CNS, Global, SWOT –Amarin, 2011 92Figure 48: Orphan Diseases Therapeutics in CNS, Global, SWOT –Siena Biotech, 2011 93Figure 49: Orphan Diseases Therapeutics in CNS, Global, SWOT –Sanofi, 2011 94Figure 50: Orphan Diseases Therapeutics in CNS, Global, M&As by Indication, 2004–2011 98Figure 51: Orphan Diseases Therapeutics in CNS Global, M&As by Geography, 2004–2011 99Figure 52: Orphan Diseases Therapeutics in CNS, Global, M&As by Value, 2004–2011 100Figure 53: Orphan Diseases Therapeutics in CNS, Global, M&As by Year, 2004–2011 101Figure 54: Orphan Diseases Therapeutics in CNS, Global, Licensing Deals by Indication, 2004–2011 107Figure 55: Orphan Diseases Therapeutics in CNS, Global, Licensing Deals by Geography, 2004–2011 108Figure 56: Orphan Diseases Therapeutics in CNS, Global, Licensing Deals by Value, 2005–2011 109Figure 57: Orphan Diseases Therapeutics in CNS, Global, Licensing Deals by Year, 2004–2011 110Figure 58: Orphan Diseases Therapeutics in CNS, Global, Co-Developments by Geography, 2004-2011 113Figure 59: Orphan Diseases Therapeutics in CNS, Global, Co-Developments by Value, 2005–2011 114Figure 60: Orphan Diseases Therapeutics in CNS, Global, Co-Developments by Year, 2005–2011 115
Companies mentioned
Biogen Idec
Avanir
Neuraltus
Cytokinetics
Avicena
NeuroSearch
Trophos
Amarin
Siena Biotech
Sanofi
To order this report:Therapy Industry: Orphan Diseases Therapeutics in CNS to 2017 - Novel Agents such as AMR101 and ACR16 to Provide Treatment Options and Boost the Huntington's Disease SegmentMore
Market Research ReportCheck our
Industry Analysis and InsightsContact
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article